The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
- To prevent relapse in patients with Ulcerative Colitis (UC) in remission after administering fecal microbiota transplant (FMT) capsules plus Standard-Of-Care (SOC) treatment compared to placebo plus SOC treatment for 12 weeks.
- To evaluate the safety of FMT capsules given orally for 12 weeks in patients with UC in remission.
To assess the safety of, as well as how a natural product derived from the Hops plant is broken down by the bacteria in the intestines of adults with Crohn’s disease.
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
This Stanford University study aims to identify potential environmental exposure markers that may contribute to the progression of Crohn's disease.
To Evaluate the Safety and Efficacy of PN-943 Treatment in Patients with Moderate to Severe Active Ulcerative Colitis.
To assess the safety and tolerability and early proof of efficacy of TAK-018 in patients with Crohn’s Disease who are planning to undergo surgery to remove the diseased ileo-cecal region of the bowel.
The primary objective is to evaluate the safety, tolerability and efficacy of two doses of etrasimod as induction therapy in participants with moderately to severely active Crohn’s disease.
The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.
Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC
Primary Objective: To Evaluate the Effect of GB004 Compared to Placebo on Clinical Remission